AG
LPCN icon

Advisor Group’s Lipocine LPCN Stock Holding History

Advisor Group’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$0 Hold
68
– – ﹤0.01% 5385
2019
Q3 		$3K Hold
68
– – ﹤0.01% 4850
2019
Q2 		$2K Hold
68
– – ﹤0.01% 4982
2019
Q1 		$3K Hold
68
– – ﹤0.01% 4851
2018
Q4 		$1K Hold
68
– – ﹤0.01% 4978
2018
Q3 		$2K Hold
68
– – ﹤0.01% 4862
2018
Q2 		$1K Hold
68
– – ﹤0.01% 4809
2018
Q1 		$2K Buy
+68
New +$1.89K ﹤0.01% 4695

Other funds holding LPCN

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
CL
Choreo LLC Rockford, Illinois $9.11B AUM 26.3% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Advisor Group's LPCN Position: Q4 2019 in Review

Advisor Group held its Lipocine (LPCN) position steady in Q4 2019 at 68 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5385.

Advisor Group first reported a position in LPCN in Q1 2018 and has held it in 8 quarters since. The position peaked at $3K in Q3 2019. 32 funds tracked by Wall St. Rank hold LPCN as of Q4 2019.

  • Advisor Group held 68 shares of Lipocine worth $0 as of Q4 2019.
  • Advisor Group left its Lipocine share count unchanged in Q4 2019.
  • Lipocine made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5385 holding.
  • Advisor Group first reported a position in Lipocine in Q1 2018 and has held it in 8 quarters since.
  • Advisor Group's Lipocine position peaked at $3K in Q3 2019.
  • 32 funds tracked by Wall St. Rank held Lipocine as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.